Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG MIX 50 50 versus NOVOLOG MIX 70 30 FLEXPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG MIX 50 50 versus NOVOLOG MIX 70 30 FLEXPEN.
NOVOLOG MIX 50/50 vs NOVOLOG MIX 70/30 FLEXPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog with rapid onset of action due to substitution of amino acid proline with aspartic acid at position B28, facilitating faster dissociation from hexamers into monomers after subcutaneous injection. Biphasic formulation containing 50% insulin aspart protamine (intermediate-acting) and 50% insulin aspart (rapid-acting).
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It replaces endogenous insulin and has a faster onset and shorter duration than regular human insulin due to altered amino acid sequence (substitution of proline at position 28 with aspartic acid).
Subcutaneous injection. Typical adult dose: 0.5 to 1 unit/kg/day divided into two injections (with breakfast and dinner). Dose is individualized based on blood glucose levels and patient needs.
Subcutaneous injection only. Initial total daily insulin dose: 0.5 to 1 unit/kg/day. Administer 70% intermediate-acting insulin aspart protamine and 30% rapid-acting insulin aspart. Typically given twice daily within 15 minutes before meals. Dose individualize based on glycemic goals.
None Documented
None Documented
6-8 hours (terminal half-life of protamine-bound fraction; free insulin component half-life ~4-5 minutes).
0.5-1 hour for the rapid-acting insulin aspart component and 8-10 hours for the protamine-crystallized insulin aspart component. Clinical context: biphasic profile allows for both prandial and basal coverage.
Renal: 50-60% as intact insulin, 30-40% as metabolites; biliary/fecal: minimal (<1%).
Renal elimination of degradation products. Approximately 30-40% of insulin dose is excreted unchanged in urine; the remainder is metabolized primarily in liver and kidney and excreted as metabolites.
Category C
Category C
Insulin Analog
Insulin Analog